Parliamentary questions can be asked by any MSP to the Scottish Government or the Scottish Parliamentary Corporate Body. The questions provide a means for MSPs to get factual and statistical information.
Urgent Questions aren't included in the Question and Answers search. There is a SPICe fact sheet listing Urgent and emergency questions.
Displaying 48968 questions Show Answers
To ask the Scottish Government whether it will provide an update on the steps that it has taken to share the necessary information with the Department for Work and Pensions to support the progress of the Scottish Government’s 2017 policy commitment to introduce automatic split payments of universal credit in Scotland.
To ask the Scottish Government how many civil servants have been dismissed for poor performance in each year since 1999.
To ask the Scottish Government what its current plans are for the site of HMP Shotts.
To ask the Scottish Government what assessment it has made of disability benefit waiting times, in light of the Young Lives vs Cancer research, The Cost of Waiting, which states that almost half of young cancer patients in Scotland finish their active treatment before receiving a decision on their disability benefit application.
To ask the Scottish Government whether it will provide the dates of the last 10 meetings of the Serious Organised Crime Taskforce, and how many of these meetings were attended by its ministers.
To ask the Scottish Government what its current plans are for the former RAF Dallachy site in Moray.
To ask the Scottish Government how many properties it currently owns.
To ask the Scottish Government what measures it is taking to reduce any barriers for patients with advanced or complex Parkinson’s disease to access Scottish Medicines Consortium-approved treatments.
To ask the Scottish Government what assessment it has made of the long-term viability of Scotland’s livestock sector, in light of the finding that 68% of lowland cattle and sheep farms were operating at a loss in 2023-24.
To ask the Scottish Government whether there are any financial or service constraints that impact on patients with advanced or complex Parkinson’s disease accessing Scottish Medicines Consortium-approved treatments.